806 results on '"Yassine, Hadi M."'
Search Results
102. Interspecies Transmission of Influenza A Viruses Between Swine and Poultry
103. Coronavirus Disease 2019 Disease Severity in Children Infected With the Omicron Variant
104. Protection against reinfection with SARS-CoV-2 omicron BA.2.75*sublineage
105. Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants
106. Assessment of Indoor Air Quality of Four Primary Health Care Centers in Qatar
107. COVID-19 Disease Severity in Persons Infected With Omicron BA.1 and BA.2 Sublineages and Association With Vaccination Status
108. Duration of immune protection of SARS-CoV-2 natural infection against reinfection
109. Effects of SARS-CoV-2 Alpha, Beta, and Delta variants, age, vaccination, and prior infection on infectiousness of SARS-CoV-2 infections
110. Microbiome engineering to combat antimicrobial resistance and upsurge productivity of food animals: a systematic review
111. Immune protection against SARS-CoV-2 re-reinfection and immune imprinting
112. Validation of a Novel Fluorescent Lateral Flow Assay for Rapid Qualitative and Quantitative Assessment of Total Anti-SARS-CoV-2 S-RBD Binding Antibody Units (BAU) from Plasma or Fingerstick Whole-Blood of COVID-19 Vaccinees
113. In silico virtual screening of lead compounds for major antigenic sites in respiratory syncytial virus fusion protein
114. Use of Hemagglutinin Stem Probes Demonstrate Prevalence of Broadly Reactive Group 1 Influenza Antibodies in Human Sera
115. Pre-fusion structure of a human coronavirus spike protein
116. Identification of Prognostic Metabolomic Biomarkers at the Interface of Mortality and Morbidity in Pre-Existing TB Cases Infected With SARS-CoV-2
117. Effectiveness of the BNT162b2 vaccine against SARS-CoV-2 infection among children and adolescents in Qatar
118. Identification of Prognostic Metabolomic Biomarkers at the Interface of Mortality and Morbidity in Pre-Existing TB Cases Infected With SARS-CoV-2
119. COVID-19 risk score as a public health tool to guide targeted testing: A demonstration study in Qatar
120. Protection of SARS-CoV-2 natural infection against reinfection with the Omicron BA.4 or BA.5 subvariants
121. Duration of immune protection of SARS-CoV-2 natural infection against reinfection in Qatar
122. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections
123. Evaluation of a novel fully automated and ELISA- based assays for detecting anti- SARS- CoV-2 neutralizing antibodies
124. Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences
125. Effects of BA.1/BA.2 subvariant, vaccination and prior infection on infectiousness of SARS-CoV-2 omicron infections
126. Soluble ACE2 and angiotensin II levels are modulated in hypertensive COVID-19 patients treated with different antihypertension drugs
127. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar
128. High but Short-lived anti-SARS-CoV2 neutralizing, IgM, IgA, and IgG levels among mRNA-vaccinees compared to naturally-infected participants
129. Immunoinformatics prediction of potential immunodominant epitopes from human coronaviruses and association with autoimmunity
130. Low risk of serological cross-reactivity between the dengue virus and SARS-CoV-2 IgG antibodies using advanced detection assays
131. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection
132. Author Correction: Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses
133. Coronavirus Disease 2019 Disease Severity in Children Infected With the Omicron Variant
134. Protection against the Omicron Variant from Previous SARS-CoV-2 Infection
135. Effect of prior infection, vaccination, and hybrid immunity against symptomatic BA.1 and BA.2 Omicron infections and severe COVID-19 in Qatar
136. Protection of prior natural infection compared to mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar
137. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
138. Will Host Genetics Affect the Response to SARS-CoV-2 Vaccines? Historical Precedents
139. Effects of BA.1/BA.2 subvariant, vaccination, and prior infection on infectiousness of SARS-CoV-2 Omicron infections
140. Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage
141. Duration of protection of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 Omicron infection in Qatar
142. Characterizing the effective reproduction number during the COVID-19 pandemic: Insights from Qatar’s experience
143. Microbiome profiling of rotavirus infected children suffering from acute gastroenteritis
144. Epidemiological and genetic characterization of pH1N1 and H3N2 influenza viruses circulated in MENA region during 2009–2017
145. Epidemiology of SARS-CoV2 in Qatar’s primary care population aged 10 years and above
146. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials
147. Potential role of viral surface glycoproteins in the replication of H3N2 triple reassortant influenza A viruses in swine and turkeys
148. Assessing the performance of a serological point-of-care test in measuring detectable antibodies against SARS-CoV-2
149. Effectiveness of BNT162b2 and mRNA-1273 COVID-19 boosters against SARS-CoV-2 Omicron (B.1.1.529) infection in Qatar
150. Antiviral activity of glucose-derived reactive metabolite, methylglyoxal against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.